Statement on COVID-19 from the Foundation's Scientific and Medical Advisory Board to the hepatitis B community
Vaccination will be key to preventing spread and reducing serious illness and death due to COVID-19. We encourage all those within the hepatitis B community to talk with their clinical care providers about getting vaccinated. Please read more here. - 12/31/20
Recent study on hepatitis B and COVID-19 According to a recently published small study from China, having hepatitis B did not effect incubation period, viral shedding or disease severity in patients who also had hepatitis B infection. This was a very small study, and more studies will be needed to fully understand the impact of hepatitis B on COVID-19 infection, but these results are good news. - 12/18/20
Impact of COVID-19 on the care of patients with liver disease, EASL position paper - 8/13/20
Hepatitis B and C Virus Considerations in COVID-19, Infectious Disease Advisor - 7/15/20
The World Hepatitis Alliance has a hub of resources for those living with viral hepatitis and are concerned with the impact COVID-19 has on their health and access to testing and treatment services. The Alliance's recent webinar on the subject is posted here. The U.S. Centers for Disease Control and Prevention (CDC) also has a new informational page: What You Need to Know About Liver Disease and COVID-19
A timely fact sheet with Information about COVID-19 for people living with chronic HBV and HCV has been posted by a coalition of organizations in Australia called Hepatitis Australia. Although there is limited information about the specific effect of COVID-19 on those living with viral hepatitis, the fact sheet provides practical advice on what to do and how to protect yourself during this difficult time.
The American Association for the Study of Liver Diseases (AASLD) has created a resource page for clinicians and researchers, including webinars and journal articles, such as “Clinical Insights for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic.” This document provides data and insights on COVID-19 and how it may affect hepatologists and liver transplant providers and their patients.
The European Association for the Study of Liver diseases (EASL) has a webpage with internal and external resources including the COVID-Hep registry for providers to report COVID-19 in patients with liver disease or transplantation. The Secure-Cirrhosis registry is also available COVID cases in patients with chronic liver disease for North America, South America, or China/Japan/Korea. Access to Journal of Hepatology articles for EASL COVID-19 is also provided.
The Hepatitis B Foundation recommends that you follow guidelines from the U.S. Centers for Disease Control and Prevention and other country or state recommendations to keep you, your family and your community safe.
Out of an abundance of caution, and in line with state and federal recommendations, the Hepatitis B Foundation staff is currently teleworking indefinitely and monitoring the COVID-19 situation daily. We are 100% business as usual, with a few notable exceptions:
- We are restricting visitors to our physical location and following all state and federal recommendations to keep our staff and community healthy.
- We are postponing all community events and switching scheduled in-person meetings to remote when possible.
- We are still responding to telephone calls to our helpline, but you will need to leave a voice message at 215-489-4900. We will return your call as soon as we can. During this time, it is best to email your hepatitis B questions to the helpline at firstname.lastname@example.org.
We recommend that you follow guidelines from the US Centers for Disease Control and Prevention to keep you, your family and your community safe.
Finally, you might find interesting this message from Dr. Timothy Block, Hepatitis B Foundation President.